Erbitux cetuximab: Additional Phase III data

Additional data from the open-label, U.K. and Irish Phase III COIN trial in 1,630 patients with previously untreated mCRC showed that Erbitux plus an oxaliplatin-based chemotherapy regimen missed the secondary endpoint of significantly improving median PFS vs. chemotherapy alone in patients with wild-type K-Ras tumors (n=729; 8.6 months for both, p=0.6). Erbitux plus chemotherapy did significantly improve overall response rate (ORR) vs. chemotherapy alone in patients with wild-type K-Ras (64% vs. 57%, p=0.049). Data were published in The Lancet. ...